Esperion loss grows as company begins selling cholesterol-fighting drugs
ANN ARBOR—Esperion Therapeutics Inc. reported a loss of $85.4 million or $3.07 a share in the third quarter of 2020, vs. a loss of $68.4 million or $2.52 a share …
Ann Arbor pharma firm rolls out nasal disinfectant
ANN ARBOR—BlueWillow Biologics, a firm founded in 1999 that is developing nanotechnology for healthcare applications, announced the availability of NanoBio Protect on Amazon. NanoBio Protect is an alcohol-free antiseptic solution that …
Esperion’s new cholesterol-buster hits the market
ANN ARBOR—After years of development, Nexletol, the new cholesterol-reducer from Ann Arbor’s Esperion Therapeutics Inc., is now on the market and available in pharmacies in the United States. Nexletol uses …
Pure Michigan Business Connect offering virtual matchmaking for COVID-19 response gear
LANSING–The Michigan Economic Development Corp.’s Pure Michigan Business Connect program is now offering a free, online procurement platform to assist suppliers of critical health and human services across a broad …
New pharma study safety software from Canton firm
CANTON TWP.—MMS Holdings Inc., a Canton Township-based contract research organization (CRO) for the pharmaceutical industry, announced the introduction of its Datacise Integrated Safety Explorer, which will debut at the Pharmaceutical …
Clinical trial evaluation firm changes name
ALLENDALE—QST Consultations Ltd. has announced that it has changed its name to Abond CRO Inc., launching the new brand through a new website and participation at participation at the Summit …
Millendo names chief commercial officer
ANN ARBOR—Millendo Therapeutics Inc. (Nasdaq: MLND), the developer of new endocrine drugs, announced the promotion of Thomas Hoover to the newly created position of chief commercial officer. Hoover joined Millendo …
GR Alzheimer’s drug developer changes name
GRAND RAPIDS—Tetra Discovery Partners, a clinical-stage biotechnology company, announced the company’s name change to Tetra Therapeutics. The name change reflects the company’s transition from a company focused on discovery research …
Pharma startup raises $5M to complete Phase 2 clinical trials
FARMINGTON HILLS—Ocuphire Pharma Inc., a clinical-stage pharmaceutical company developing therapies to treat patients with a variety of ophthalmic disorders, announced that it has closed on over $5 million of financing. …
OptimizeRx raises $20 million in stock offering
(Updated June 5 with stock price) ROCHESTER—OptimizeRx Corp. (Nasdaq: OPRX), the Rochester-based provider of digital communication services for pharmaceutical companies to patients and healthcare providers, has announced a proposed underwritten …